DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy
DexCom Insiders Sold US$18m Of Shares Suggesting Hesitancy
Over the past year, many DexCom, Inc. (NASDAQ:DXCM) insiders sold a significant stake in the company which may have piqued investors' interest. Knowing whether insiders are buying is usually more helpful when evaluating insider transactions, as insider selling can have various explanations. However, if numerous insiders are selling, shareholders should investigate more.
在过去的一年中，德康医疗股份有限公司（纳斯达克股票交易代码：DXCM）的许多内部人士出售了该公司的大量股份，这可能引起了投资者的兴趣。当评估内部人员交易时，了解内部人员是否购买的情况通常更有帮助，因为内部人员出售股票可能有各种解释。但是，如果有很多内部人士在出售股票，股东就应该进一步调查。
While insider transactions are not the most important thing when it comes to long-term investing, logic dictates you should pay some attention to whether insiders are buying or selling shares.
尽管在长期投资中内部交易并不是最重要的事情，但从逻辑上讲，您应该关注内部人员是否买入或出售股票。
The Last 12 Months Of Insider Transactions At DexCom
德康医疗公司内部交易的最后12个月
Over the last year, we can see that the biggest insider sale was by the Executive Chairman, Kevin Sayer, for US$4.6m worth of shares, at about US$124 per share. So we know that an insider sold shares at around the present share price of US$113. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. Given that the sale took place at around current prices, it makes us a little cautious but is hardly a major concern.
在过去一年中，我们可以看到最大的内部人员销售是由执行主席Kevin Sayer进行的，价值460万美元的股票，每股售价约为124美元。因此，我们知道一位内部人员以现价113美元左右的价格出售了股票。我们通常不喜欢看到内部人员出售股票，但是销售价格越低，我们就越担忧。考虑到出售是以目前价格为基准进行的，这使我们有点谨慎，但并不是一个主要问题。
In the last year DexCom insiders didn't buy any company stock. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!
在过去的一年中，德康医疗公司内部人员没有购买任何公司股票。您可以在下面看到（按公司和个人）过去12个月内部交易的视觉呈现。如果您想知道谁以多少钱何时出售股票，只需单击下面的图表！
For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.
对于那些喜欢发现潜力股票的人，可以免费查看最新内部交易股票的小盘公司名单，这可能正是您要找的机会。
Insiders At DexCom Have Sold Stock Recently
德康医疗公司内部人员最近出售了股票
The last three months saw significant insider selling at DexCom. In total, insiders sold US$221k worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.
最近三个月，德康医疗公司发生了大量内部人员销售。总计，内部人员在那段时间内售出了22.1万美元的股票，我们没有记录任何购买。总体而言，这让我们有点谨慎，但这不是全部。
Insider Ownership
内部人员持股情况
Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. DexCom insiders own 0.4% of the company, currently worth about US$178m based on the recent share price. Most shareholders would be happy to see this sort of insider ownership, since it suggests that management incentives are well aligned with other shareholders.
测试公司领导层与其他股东之间对齐的另一种方法是查看他们拥有多少股票。通常来说，内部所有权越高，内部人员就越有可能受到激励为长期建设公司而努力。德康医疗公司内部人员拥有该公司的0.4％股份，根据最近的股票价格，价值约1.78亿美元。大多数股东会很高兴看到这种内部所有权，因为这意味着管理层的激励与其他股东的利益保持一致。
What Might The Insider Transactions At DexCom Tell Us?
德康医疗公司的内部交易可能告诉我们什么？
Insiders sold stock recently, but they haven't been buying. And even if we look at the last year, we didn't see any purchases. But since DexCom is profitable and growing, we're not too worried by this. The company boasts high insider ownership, but we're a little hesitant, given the history of share sales. So these insider transactions can help us build a thesis about the stock, but it's also worthwhile knowing the risks facing this company. In terms of investment risks, we've identified 1 warning sign with DexCom and understanding it should be part of your investment process.
内部人员最近出售了股票，但他们没有购买。即使我们看过去一年的情况，我们也没有看到任何购买。但由于德康医疗公司盈利且发展良好，我们对此并不太担心。该公司拥有较高的内部所有权，但鉴于股票出售的历史，我们有点犹豫。因此，这些内部交易可以帮助我们建立有关该股票的论点，但了解面临的风险也很有价值。在投资风险方面，我们已确定德康医疗公司有1个警告信号，了解它应该成为您的投资过程的一部分。
Of course DexCom may not be the best stock to buy. So you may wish to see this free collection of high quality companies.
当然，德康医疗公司可能不是最好的购买股票的选择。因此，您可能希望查看这些高质量公司的免费收藏品。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
对于本文而言，内部人是指向相关监管机构报告其交易的个人。我们目前仅考虑公开市场交易和直接利益的私人处置，但不包括衍生交易或间接利益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈？关注内容？请直接与我们联系。或者，发送电子邮件至editorial-team@simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论，只使用公正的方法论，我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议，也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意，我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈？ 对内容感到担忧？ 请直接与我们联系。 或者，发送电子邮件至editorial-team@simplywallst.com。